Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥443.9bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥228.6bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥66.5bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥36.8bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥66.4bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥36.6bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥1.75Tat 2023-09-30Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.66Tat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.26Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.26Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥187.3bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥53.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥36.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥30.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥67.272023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.992023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥67.242023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.972023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥119m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥84.1bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥10.6bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥265.7bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥57.6bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥94.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥8.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥443.8bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥76.6bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 690
ItemContextValueUnit
Profit loss IFRSCurrentYTDDuration50092000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration53.37
Basic earnings loss per share IFRSCurrentYTDDuration67.27
Diluted earnings loss per share IFRSPrior1YTDDuration53.35
Diluted earnings loss per share IFRSCurrentYTDDuration67.24
Revenue IFRSPrior1QuarterDuration205976000000JPY
Revenue IFRSCurrentQuarterDuration228621000000JPY
Cost of sales IFRSPrior1QuarterDuration100620000000JPY
Cost of sales IFRSCurrentQuarterDuration110165000000JPY
Gross profit IFRSPrior1QuarterDuration105355000000JPY
Gross profit IFRSCurrentQuarterDuration118455000000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration76142000000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration82761000000JPY
Other income IFRSPrior1QuarterDuration1375000000JPY
Other income IFRSCurrentQuarterDuration2179000000JPY
Other expenses IFRSPrior1QuarterDuration5038000000JPY
Other expenses IFRSCurrentQuarterDuration1025000000JPY
Operating profit loss IFRSPrior1QuarterDuration25549000000JPY
Operating profit loss IFRSCurrentQuarterDuration36848000000JPY
Finance income IFRSPrior1QuarterDuration414000000JPY
Finance income IFRSCurrentQuarterDuration737000000JPY
Finance costs IFRSPrior1QuarterDuration714000000JPY
Finance costs IFRSCurrentQuarterDuration1051000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration-292000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration89000000JPY
Profit loss before tax IFRSPrior1QuarterDuration24957000000JPY
Profit loss before tax IFRSCurrentQuarterDuration36623000000JPY
Income tax expense IFRSPrior1QuarterDuration7034000000JPY
Income tax expense IFRSCurrentQuarterDuration9081000000JPY
Profit loss IFRSPrior1QuarterDuration17922000000JPY
Profit loss IFRSCurrentQuarterDuration27542000000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration17922000000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration27542000000JPY
Profit loss IFRSPrior1QuarterDuration17922000000JPY
Profit loss IFRSCurrentQuarterDuration27542000000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration23.75
Basic earnings loss per share IFRSCurrentQuarterDuration36.99
Diluted earnings loss per share IFRSPrior1QuarterDuration23.74
Diluted earnings loss per share IFRSCurrentQuarterDuration36.97
Profit loss IFRSPrior1YTDDuration40321000000JPY
Profit loss IFRSCurrentYTDDuration50092000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration1889000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration661000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration918000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration123000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration2808000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration784000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration143340000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration114426000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration452000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass